康复新液联用益生菌治疗溃疡性结肠炎Meta分析

Meta-analysis of Kangfuxin Liquid Combined with Probiotics in Treating Ulcerative Colitis

目的：评价康复新液联用益生菌治疗溃疡性结肠炎（UC）的有效性及安全性。方法：计算机检索Cochrane Library、Pub Med、Embase、中国生物医学文献数据库（CBM）,中国科技期刊全文数据库（VIP）,中国期刊全文数据库（CNKI）和万方数据库,收集关于康复新液联用益生菌治疗溃疡性结肠炎的随机对照试验。由两名研究者独立进行资料提取和文献质量评价,采用Rev Man 5. 3软件进行Meta分析。结果：最终纳入11个RCT,1022例患者。Meta分析结果显示,与对照组相比,试验组能够明显提高溃疡性结肠炎治疗的临床有效率[OR=5. 59,95%CI （3. 52,8. 88）,P 〈0. 00001],改善结肠镜下黏膜病变疗效,但不能降低不良反应发生率[OR=1. 27,95%CI（0. 60,2. 69）,P=0. 53]。漏斗图分析显示不对称,可能存在发表偏倚。结论：康复新液联用益生菌对溃疡性结肠炎有更好的疗效,但由于纳入文献质量较低,且文献数量偏少,需要进一步开展更多高质量、大样本的随机双盲试验。

Objective： To systematically evaluate the clinical efficacy and safety of Kangfuxin Liquid combined with probiotics in treating ulcerative colitis. Methods： Databases such as Cochrane Library,Pub Med,Embase,CBM,VIP,CNKI and Wanfang were searched for randomized controlled trials about Kangfuxin Liquid combined with probiotics as the interventions for ulcerative colitis. Two researchers independently screened the literature,extracted the data and evaluated the methodological quality according to the inclusion and exclusion criteria. Rev Man 5. 3 was used to revaluate the results of the total effect of Meta-analysis. Results： Eleven RCTs involving 1022 patients were included into the study. The Meta-analysis results showed that compared with the control group,Kangfuxin Liquid combined with probiotics can significantly improve the clinical effective rate[OR = 5. 59,95% CI（3.52,8. 88）,P 0. 00001],improve the endoscopic mucosal lesions,but can not significantly reduce adverse reactions incidence[OR = 1. 27,95% CI（0. 60,2. 69）,P = 0. 53]. Funnel plot analysis showed potential bias. Conclusion： Kangfuxin Liquid combined with probiotics in treatment of ulcerative colitis has good therapeutic effect. However,due to the low methodology and less study,more high-quality,double-blind trials with a large sample size are required to further evaluate the efficacy and safety of Kangfuxin Liquid combined with probiotics in treating ulcerative colitis.